α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity

(2018) David Wang et al.   Cell Reports

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

(2018) Rikke B. Holmgaard et al.   Journal for ImmunoTherapy of Cancer

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

(2017) Frederick Arce Vargas et al.   IMMUNITY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma

(2017) Axel Lechner et al.   Oncotarget

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy

(2017) Masaki Terabe et al.   OncoImmunology

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

(2016) B. V. Park et al.   Cancer Discovery

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

(2016) Gulidanna Shayan et al.   OncoImmunology

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

(2015) Claire Vanpouille-Box et al.   CANCER RESEARCH

Upregulation of PD-1 on CD4+CD25+T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis

(2015) Xiaolin La et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells

(2015) Pablo Penaloza-MacMaster et al.   JOURNAL OF IMMUNOLOGY

Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms

(2015) Daniel Bedinger et al.   mAbs

Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers

(2015) Melissa Q McCreery et al.   NATURE MEDICINE

The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types

(2015) Peter S. Linsley et al.   PLoS One

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

Genetic variants of Adam17 differentially regulate TGF  signaling to modify vascular pathology in mice and humans

(2014) K. Kawasaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

(2013) Matthew D. Vesely et al.   Annals of the New York Academy of Sciences

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

Tgf-β1 produced by activated CD4+T Cells Antagonizes T Cell Surveillance of Tumor Development

(2012) Moses K. Donkor et al.   OncoImmunology

Outgrowth of Drug-Resistant Carcinomas Expressing Markers of Tumor Aggression after Long-term T RI/II Kinase Inhibition with LY2109761

(2011) E. C. Connolly et al.   CANCER RESEARCH

Preferential Expression of Integrin αvβ8 Promotes Generation of Regulatory T Cells by Mouse CD103+ Dendritic Cells

(2011) Helena Païdassi et al.   GASTROENTEROLOGY

T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine

(2011) Moses K. Donkor et al.   IMMUNITY

Human CD141+(BDCA-3)+dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens

(2010) Sarah L. Jongbloed et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor  

(2008) S. Wei et al.   CANCER RESEARCH

Molecular Antagonism and Plasticity of Regulatory and Inflammatory T Cell Programs

(2008) Xuexian O. Yang et al.   IMMUNITY

Germline Allele-Specific Expression of TGFBR1 Confers an Increased Risk of Colorectal Cancer

(2008) L. Valle et al.   SCIENCE